April 28, 2021 11:04 AM EDTUpdated April 30, 01:19 PM

BeiGene's late stage trial shows promising numbers; Amgen to study sotorasib dosage after FDA recommendation

John Carroll

Editor & Founder

Josh Sullivan

Big Chinese pharma player BeiGene $BGNE is showing off some promising numbers from its interim analysis of a late-stage, head-to-head trial pitting their BTK drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BeiGene's late stage trial shows promising numbers; Amgen to study sotorasib dosage after FDA recommendation

John Carroll

Editor & Founder

Josh Sullivan

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

BeiGene's late stage tri­al shows promis­ing num­bers; Am­gen to study so­tora­sib dosage af­ter FDA rec­om­men­da­tion

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

BeiGene's late stage trial shows promising numbers; Amgen to study sotorasib dosage after FDA recommendation